Alentis Therapeutics

Alentis Therapeutics is a private, clinical-stage biotechnology company headquartered in Basel, Switzerland, and is a leader in targeting Claudin-1 (CLDN1). Its pipeline includes the ADC ALE.P02 for squamous cancers and the monoclonal antibody lixudebart (ALE.F02) for organ fibrosis, both in clinical development. The company was founded on over 15 years of foundational research and is led by a seasoned team, including CEO Mark Pruzanski, a veteran biotech entrepreneur. Alentis aims to address significant unmet needs in oncology and fibrotic diseases through its novel Claudin-1-targeting platform.

First-in-class antibodies and antibody-drug conjugates (ADCs) targeting exposed Claudin-1 (CLDN1), a tight junction protein, to treat cancer and reverse fibrosis.

In fibrosis, Alentis competes with numerous biopharma companies developing anti-fibrotics, though its reversal mechanism is distinct. In oncology, it faces competition from other ADC developers and targeted therapies for squamous cancers. Its key differentiator is the first-in-class focus on exposed CLDN1.